1. Scrip
  2. >>Business

Dupixent Keeps Sanofi At Forefront Of European Pharma Growth

Hints At Raised Forecast For Blockbuster

 
• By Andrew McConaghie

Sanofi is on a roll thanks to Dupixent and the blockbuster is providing breathing space even when some key pipeline assets are delayed.

Sanofi_Berlin
A forecast 14% rise in earnings per share in 2021 will put Sanofi among the top European big pharma performers. • Source: Alamy

Revenues from allergic diseases blockbuster Dupixent have outstripped expectations in the third quarter, helping to lift overall Sanofi sales by 10% to €10.4 bn ($11.65bn) during the period.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Zelluna Believes Its TCR Tech Can Unlock Natural Killer Cell Potential

 
• By Andrew McConaghie

While CAR-NKs have pivoted towards autoimmune disease, the Norwegian biotech believes its unique platform can deliver in oncology

AstraZeneca COPD Drug Breztri Breezes Through Asthma Trials

 
• By Kevin Grogan

The triple therapy improves lung function in the Phase III KALOS and LOGOS studies

Transient FY26 For Syngene But Momentum In China +1 Projects

 
• By Anju Ghangurde

As biopharma derisks its business with China ‘rebalancing’ strategies, Syngene could convert majority of such pilots into full program contracts amid a challenging FY2025. The CRDMO also expects business discussions pertaining to a newly acquired US biologics site to mature into commercial opportunities.